|
Market Closed -
Nasdaq
21:00:00 08/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.320 USD | -1.82% |
|
+6.93% | +168.32% |
| 08-17 | B. Riley Raises Price Target on MacroGenics to $11 From $9, Keeps Buy Rating | MT |
| 08-13 | MacroGenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 275M | - | - | - | ||
| 69.19B | |||||
| 62.97B | |||||
| 27.27B | - | ||||
| 24.78B | - | ||||
| 25.8B |
- Stock Market
- Stocks
- MGNX Stock
- Charts MacroGenics, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
